November 25, 2019 / 8:35 PM / 6 months ago

FDA approves Global Blood Therapeutics's sickle cell disease drug

Nov 25 (Reuters) - The U.S. Food and Drug Administration said on Monday that it had approved Global Blood Therapeutics's drug, Oxbryta, to treat sickle cell disease in adults and pediatric patients aged 12 years or older.

The disease is a lifelong, inherited blood disorder in which abnormally shaped red blood cells restrict flow of blood in vessels, leading to severe pain and organ damage.

The approval comes three months ahead of the previously set target date by the agency. (Reporting by Trisha Roy in Bengaluru; Editing by Anil D'Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below